Back to discover

Protein / target

Sodium/glucose cotransporter 1

Encoded bySLC5A1P13866Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Alpha-glucoside transmembrane transporter

Strongest disease association

Diabetes Mellitus, Type 2

Via encoding gene SLC5A1 · Genetic evidence · score 0.12

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose or D-galactose at the plasma membrane, with a Na(+) to sugar coupling ratio of 2:1.

View complete UniProt function annotation

Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose or D-galactose at the plasma membrane, with a Na(+) to sugar coupling ratio of 2:1. Transporter activity is driven by a transmembrane Na(+) electrochemical gradient set by the Na(+)/K(+) pump (PubMed:20980548, PubMed:34880492, PubMed:35077764, PubMed:8563765, PubMed:37217492). Has a primary role in the transport of dietary monosaccharides from enterocytes to blood. Responsible for the absorption of D-glucose or D-galactose across the apical brush-border membrane of enterocytes, whereas basolateral exit is provided by GLUT2. Additionally, functions as a D-glucose sensor in enteroendocrine cells, triggering the secretion of the incretins GCG and GIP that control food intake and energy homeostasis (By similarity) (PubMed:8563765). Together with SGLT2, functions in reabsorption of D-glucose from glomerular filtrate, playing a nonredundant role in the S3 segment of the proximal tubules (By similarity). Transports D-glucose into endometrial epithelial cells, controlling glycogen synthesis and nutritional support for the embryo as well as the decidual transformation of endometrium prior to conception (PubMed:28974690). Acts as a water channel enabling passive water transport across the plasma membrane in response to the osmotic gradient created upon sugar and Na(+) uptake. Has high water conductivity, comparable to aquaporins, and therefore is expected to play an important role in transepithelial water permeability, especially in the small intestine

Subcellular location

Apical cell membrane
Domains and Gene Ontology detail (29)

Gene Ontology

  • Capical plasma membrane
  • Cbrush border membrane
  • Cearly endosome
  • Cextracellular exosome
  • Cintracellular vesicle
  • Cperinuclear region of cytoplasm
  • Cplasma membrane
  • Falpha-glucoside transmembrane transporter activity
  • FD-glucose transmembrane transporter activity
  • FD-glucose:sodium symporter activity
  • Ffucose transmembrane transporter activity
  • Fgalactose transmembrane transporter activity

664 aa · 73 kDa · 2 isoforms

Approved medicines with mapped indications

1 medicine · 5 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Diabetes Mellitus1 medicine
Diabetes Mellitus, Type 11 medicine
Diabetes Mellitus, Type 21 medicine
Heart Failure1 medicine
Renal Insufficiency, Chronic1 medicine

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

sotagliflozin
Narrow target profileApprovedInhibitor

Sodium/glucose cotransporter 1 inhibitor

Indicated for Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Heart Failure

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene SLC5A1

Gene-level evidence surfaced through the gene SLC5A1 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Diabetes Mellitus, Type 2
0.71Moderately supported

Clinical evidence dominant · Open Targets 0.54

Heart Failure
0.65Moderately supported

Clinical evidence dominant · Open Targets 0.52

Diabetes Mellitus, Type 1
0.63Moderately supported

Clinical evidence dominant · Open Targets 0.51

Kidney Failure, Chronic
0.58Moderately supported

Clinical evidence dominant · Open Targets 0.47

Diabetes Mellitus
0.50Moderately supported

Clinical evidence dominant · Open Targets 0.39

View evidence synthesis (5)
Diabetes Mellitus, Type 2Moderately supported
0.71
agreement 0.600.81
Clinical77%Genetic14%Literature9%

Open Targets aggregate 0.54 · 3 independent evidence families

Heart FailureModerately supported
0.65
agreement 0.490.80
Clinical96%Literature4%

Open Targets aggregate 0.52 · 2 independent evidence families

Diabetes Mellitus, Type 1Moderately supported
0.63
agreement 0.480.79
Clinical95%Literature6%

Open Targets aggregate 0.51 · 2 independent evidence families

Kidney Failure, ChronicModerately supported
0.58
agreement 0.430.74
Clinical97%Literature3%

Open Targets aggregate 0.47 · 2 independent evidence families

Diabetes MellitusModerately supported
0.50
agreement 0.340.66
Clinical85%Literature15%

Open Targets aggregate 0.39 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Diabetes Mellitus, Type 20.54
Heart Failure0.52
Diabetes Mellitus, Type 10.51
Kidney Failure, Chronic0.47
Diabetes Mellitus0.39
Diabetic Nephropathies0.28
Cardiomyopathy, Hypertrophic0.27

Drug development

2 compounds recorded · 1 approved · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (2)
LICOGLIFLOZINPhase 2
SOTAGLIFLOZINApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (small molecule binder) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (8)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ACTIVE_NOT_RECRUITING · via sotagliflozin · NCT05696366

ClinicalTrials.gov via the drug-target graph.

What's happening now

4

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Trial status changed2026-08-26

    A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in symptomATic Obstructive And Non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)

    Status changed to Active, not recruiting · ClinicalTrials.gov · via sotagliflozin

  2. Label change2026-08-06

    Label change: SOTAGLIFLOZIN (NDA216203)

    fda · regulatory · fda · via sotagliflozin

  3. Regulatory approval2023-05-26

    Approval: SOTAGLIFLOZIN (NDA216203)

    fda · regulatory · fda · via sotagliflozin

  4. New publication2020-11-16
    Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.

    The New England journal of medicine · 2021 · 1,319 citations · Europe PMC · via sotagliflozin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.